BiotechTube
Supira Medical

Supira Medical

Santa Clara, United States· Est.
supiramedical.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $25M

Overview

Supira Medical is advancing a novel pVAD platform aimed at addressing significant unmet needs in high-risk interventional cardiology and acute heart failure. The company has generated clinical data from 99 patients across international early feasibility studies and is preparing for a U.S. pivotal trial. With a leadership team boasting extensive experience from major medtech firms, Supira is positioning its device as a potential best-in-class solution by combining low vascular access profile with high flow rates to minimize complications and avoid device escalation.

Cardiovascular

Technology Platform

Next-generation percutaneous ventricular assist device (pVAD) platform designed for low vascular access profile and high continuous blood flow, intended for temporary mechanical circulatory support in high-risk PCI and cardiogenic shock.

Funding History

1
Total raised:$25M
Series A$25M

Opportunities

The large and growing market for temporary mechanical circulatory support, driven by complex coronary disease and cardiogenic shock, presents a significant opportunity.
Supira's device, if it successfully combines low profile with high flow, could address a key unmet need by potentially reducing vascular complications and eliminating the need for device escalation, positioning it favorably against current standards of care.

Risk Factors

Key risks include failure to demonstrate safety and efficacy in the critical U.S.
pivotal trial (SUPPORT II), facing intense competition from established market leaders with strong commercial footprints, and the challenge of securing sufficient capital to fund development and future commercialization in a competitive financing environment.

Competitive Landscape

The market is dominated by Abiomed's Impella family of pVADs, with other competitors including the intra-aortic balloon pump (IABP) and larger extracorporeal membrane oxygenation (ECMO) or centrifugal flow systems. Supira's strategy is to differentiate on a technical profile that offers the high flow of larger devices through a lower-profile access, aiming to reduce complications and simplify clinical use.

More companies in Diagnostics & Precision Medicine →More companies in United States →